Disclosures: Catherine Mezzacappa: Nothing to Disclose, Pedro Ochoa-Allemant: Nothing to Disclose, Marina Serper: Transplant Genomics: Grant/Research Support, Grifols: Grant/Research Support, Eurofins: Grant/Research Support, Tamar Taddei: Nothing to Disclose, Binu John: Exact Sciences: Grant/Research Support, Genentech: Grant/Research Support, Glycotest, Inc: Grant/Research Support, Gilead: Grant/Research Support, Exelixis: Consultant, Takeda: Grant/Research Support, GlaxoSmithKline: Consultant, Astra Zeneca: Consultant, David Kaplan: AstraZeneca Inc: Grant/Research Support, Roche Genentech: Independent Contractor, Exact Sciences: Grant/Research Support, Glycotest: Grant/Research Support, Sirtex: Advisor, Exelixis: Advisor, AstraZeneca: Advisor, Nadim Mahmud: Nothing to Disclose 1081 THYROID DISORDERS (HYPOTHYRODISM AND HYPERTHYRODISM) AND THEIR ASSOCIATIONS WITH NONALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS: A STUDY ON INPATIENT OUTCOMES, INCIDENCE AND PREVALENCE Anwar Uddin Madia Ahad 1 Rafat Uddin 1 Selome Yewedalsew 1 Prashil Dave 1 Dipsa Shastri 2 Afgal Ahad 1 Rahat Uddin 1 Peter Lymberopoulos 1 Nazeera Ghanie 1 Sahil Chaddha 3 , 1 State University of New York Downstate, 2 East Tennessee State University, 3 SUNY Downstate Medical Center Background: Thyroid disorders are one of most common comorbid conditions present in patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)
Molecular Formula: CHNO Description: Ipamorelin is a selective ghrelin receptor agonist utilized in endocrine research
To maintain transparency and uphold our quality standards, we provide Certificates of Analysis (COAs) issued by an independent, accredited laboratory
J Biol Chem 288:3450234513
McCown, Sam
Telomere attrition: The shortening of chromosomal ends leading to replicative senescence
